Sarepta Therapeutics (SRPT) Gains Into Equity Pricing

September 22, 2016 11:42 AM EDT

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Sarepta Therapeutics (NASDAQ: SRPT), which has a pending $225M equity pricing, continues to surge higher. Shares are up 6.7% to $60. The stock is now up 120% since announcing FDA approval.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Equity Offerings, Trader Talk

Add Your Comment